FindTrial
Sign In

Development of pharmacogenetic biomarkers predicting anti-tuberculous drug-induced adverse drug reaction

Development of pharmacogenetic biomarkers and its clinical validation that can predict anti-tuberculous drug-induced adverse drug reaction and drug-induced hepatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0000591
Enrollment
500
Registered
2012-11-28
Start date
2012-06-26
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Dankook Univeristy Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adverse reactions to antituberculosis drugs - cutaneous reactions - liver injury: increase in AST, ALT or ALP

Exclusion criteria

Exclusion criteria: Refused to be enrolled

Design outcomes

Primary

MeasureTime frame
Frequency of gentic variants—

Secondary

MeasureTime frame
demographic and clinical parameters such as age and comorbidity—

Countries

Korea, Republic of

Contacts

Public ContactSang-Heon Kim

Hanyang University Seoul Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026